Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thermo-Life deal highlights pharma absence from diagnostics M&A

This article was originally published in Scrip

Executive Summary

Thermo Fisher’s offer to acquire Life Technologies Corp for around $13.8 billion made on 15 April underlines the apparent distance between the pharmaceutical industry and the diagnostic arena. Thermo Fisher is a scientific equipment supplier and has picked up part of the leading edge of sequence-based diagnostics. It offered $76 per share for Life, making the acquisition worth twice what Roche – surely the most diagnostically oriented pharma company - offered for another sequencing firm, Illumina, a year ago. So when will pharma get more involved? A recent white paper from Citeline suggests that diagnostic consolidation may be a transitional phase during which enlargement and tool-kit refinement occurs, creating precursors companies that are more rounded and perhaps ready for acquisition by pharma.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts